Oncology pp 1349-1362 | Cite as

Oral Complications of Cancer Therapy

  • Mark S. Chambers
  • Adam S. Garden
Chapter

Abstract

Many patients receive cytotoxic therapies that result in complications to the oral mucosa. Other patients receive either radiation or surgery as treatment of malignancies involving the head and neck region, with resultant consequences to the normal structures of the oral cavity and pharynx.

Keywords

Neck Cancer Bone Marrow Transplantation Oral Cavity Radiat Oncol Biol Phys Oral Mucositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    King G, Toth B, Fleming T. Oral dental care of the cancer patient. Texas Dent J 1988;105:10–11.PubMedGoogle Scholar
  2. 2.
    Chambers M, Toth BB, Martin JW, Fleming TJ, Lemon JC. Oral and dental management of the cancer patient: prevention and treatment of complications. Support Care Cancer 1995;3:168–175.PubMedCrossRefGoogle Scholar
  3. 3.
    National Institutes of Health Consensus Development Conference Statement. Oral complications of cancer therapies: diagnosis, prevention, and treatment. J Am Dent Assoc 1989;119:179–183.Google Scholar
  4. 4.
    Toth B, Martin JW, Fleming TJ. Oral and dental care associated with cancer therapy. Cancer Bull 1991;43:397–402.Google Scholar
  5. 5.
    Toth B, Fleming TJ. Oral care for the patient with cancer. Highlights Antineoplastic Drugs 1990;8:27–35.Google Scholar
  6. 6.
    Hurst P. Dental considerations in management of head and neck cancer. Otolaryngol Clin N Am 1985;18:573–603.Google Scholar
  7. 7.
    Lockhart P, Clark J. Pretherapy dental status of patients with malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1994;77:236–241.PubMedCrossRefGoogle Scholar
  8. 8.
    Marciani R, Ownby HE. Treating patients before and after irradiation. J Am Dent Assoc 1992;123:108–112.PubMedGoogle Scholar
  9. 9.
    Niehaus C, Meiller TF, Peterson DE, Overholser CD. Oral complications in children during cancer therapy. Cancer Nurs 1987;10:15–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Peters E, Monopoli M, Woo SB, Sonis S. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1993;76:45–48.PubMedCrossRefGoogle Scholar
  11. 11.
    Wescott W. Dental management of patients being treated for oral cancer. Can Dent Asssoc J 1987;13:42–47.Google Scholar
  12. 12.
    Toth B, Chambers M, Fleming T, et al. Minimizing oral complications of cancer treatment. Oncology 1995;9:851–858.PubMedGoogle Scholar
  13. 13.
    Toth B, Chambers MS, Fleming TJ. Prevention and management of oral complications associated with cancer therapies: radiotherapy/chemotherapy. Texas Dent J 1996;113:23–29.PubMedGoogle Scholar
  14. 14.
    Fleming T. Oral tissue changes of radiation-oncology and their management. Dent Clin N Am 1990;34:223–237.PubMedGoogle Scholar
  15. 15.
    Shrout M. Managing patients undergoing radiation. J Am Dent Assoc 1991;122:69–70, 72.PubMedGoogle Scholar
  16. 16.
    Marciani RH. Osteoradionecrosis of the jaws. J Oral Maxillofac Surg 1986;4:218–223.Google Scholar
  17. 17.
    Barrett A, Porter SR, Scully C, Eveson JW, Griffiths MJ. Oral melanotic macules that develop after radiation therapy. Oral Surg Oral Med Oral Pathol 194;77:431–434.Google Scholar
  18. 18.
    Rothwell B. Prevention and treatment of the orofacial complications of radiotherapy. J Am Dent Assoc 1987;114:316–322.PubMedGoogle Scholar
  19. 19.
    Fleming P. Dental management of the pediatric oncology patient. Curr Opin Dent 1991;1:577–582.PubMedGoogle Scholar
  20. 20.
    Brown A, Sims RE, Raybould TP, Lillich TT, Henslee PJ, Feretti GA. Oral gram-negative bacilli in bone marrow transplant patients given chlorhexidine rinses. J Dent Res 19889;68:1199–1204.Google Scholar
  21. 21.
    Dahllöf G, Krekmanova L, Kopp S, Borgström B, Forsberg CM, Ringden O. Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontol Scand 1994;52:99–105.PubMedCrossRefGoogle Scholar
  22. 22.
    Dahllöf G, Rozell B, Forsberg CM, Borgström B. Histologic changes in dental morphology induced by high dose chemotherapy and total body irradiation. Oral Surg Oral Med Oral Pathol 1994;77:56–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Dury D, Roberts NW, Miser JS, Folio J. Dental root agenesis secondary to irradiation therapy in a case of rhabdomyosarcoma of the middle ear. Oral Surg Oral Med Oral Pathol 1984;57:595–599.PubMedCrossRefGoogle Scholar
  24. 24.
    Dahllöf G, Barr M, Bolme P, et al. Disturbances in dental development after total body irradiation in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1988;65:41–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Dahllöf G, Forsberg CM, Ringden O, et al. Facial growth and morphology in long-term survivors after bone marrow transplantation. Eur J Orthod 1989;11:332–340.PubMedGoogle Scholar
  26. 26.
    Grotz K, Genitsariotis S, Vehling D, Al-Nawas B. Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy. Support Care Cancer 2003;11(11):717–721.PubMedCrossRefGoogle Scholar
  27. 27.
    Dahiya M, Redding SW, Dahiya RS, et al. Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;57:79–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Bergman O. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol 1988;26:2105–2109.Google Scholar
  29. 29.
    Toth B, Martin JW, Chambers MS, Robinson KA, Andersson BS. Oral candidiasis: a morbid sequelae of anticancer therapy. Texas Dent J 1998;115:24–29.PubMedGoogle Scholar
  30. 30.
    Denham J, Hauer-Jensen M. The radiotherapeutic injury—a complex ‘wound’. Radiother Oncol 2002;63:129–145.PubMedCrossRefGoogle Scholar
  31. 31.
    Garden A. Mucositis: current management and investigations. Semin Radiat Oncol 2003;13:267–273.PubMedCrossRefGoogle Scholar
  32. 32.
    Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991;5:11–18.PubMedGoogle Scholar
  33. 33.
    Poulsen M, Denham JW, Peters LJ, et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 2001;60:113–122.PubMedCrossRefGoogle Scholar
  34. 34.
    Bentzen S, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60:123–125.PubMedCrossRefGoogle Scholar
  35. 35.
    Parulekar W, Mackenzie R, Bjarnason G, Jordan RCK. Scoring oral mucositis. Oral Oncol 1998;34:63–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23:2–16.PubMedGoogle Scholar
  37. 37.
    Brizel D, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339–3345.PubMedGoogle Scholar
  38. 38.
    Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000;46:1105–1108.PubMedCrossRefGoogle Scholar
  39. 39.
    Buntzel J, Schuth J, Kuttner K, et al. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998;6:155–160.PubMedCrossRefGoogle Scholar
  40. 40.
    Sonis S, Peterson RL, Edwards LJ, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000;36:373–381.PubMedCrossRefGoogle Scholar
  41. 41.
    Potten C. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survivial time. Stem Cells 1996;14:452–459.PubMedCrossRefGoogle Scholar
  42. 42.
    Booth D, Haley J, Bruskin A, et al. Transforming growth factor b3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem cell cycling. Int J Cancer 2000;86:53–59.PubMedCrossRefGoogle Scholar
  43. 43.
    Sonis S. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced mucositis. Oral Oncol 1997;33:47–54.PubMedGoogle Scholar
  44. 44.
    Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002;52:911–917.PubMedCrossRefGoogle Scholar
  45. 45.
    Spielberger R, Still P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing peripheral progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 2 trial. Proc ASCO 2001;20:7a.Google Scholar
  46. 46.
    Kaplan G, Walsh G, Guido L, et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992;175:1717–1728.PubMedCrossRefGoogle Scholar
  47. 47.
    Nemunaitis J, Rosenfeld C, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:949–954.PubMedGoogle Scholar
  48. 48.
    Makkonen T. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiationinduced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys 2000;46:525–534.PubMedCrossRefGoogle Scholar
  49. 49.
    Rosso M. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J Chemother 1997;9:382–385.PubMedGoogle Scholar
  50. 50.
    Mantovani G, Massa E, Astara G, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy-and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep 2003;10:197–206.PubMedGoogle Scholar
  51. 51.
    Sprinzl G, Galvan O, De Vries A, et al. Local application of granulocyte-macrophage stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer 2001;37:2003–2009.PubMedCrossRefGoogle Scholar
  52. 52.
    Scherlacher A, Beaufort-Spontin F. Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment. HNO 1990;38:24–28.PubMedGoogle Scholar
  53. 53.
    Epstein J, Wong F. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 1994;28:693–698.PubMedGoogle Scholar
  54. 54.
    Etiz D, Erkal H, Serin M, et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 2000;36:116–120.PubMedCrossRefGoogle Scholar
  55. 55.
    Carter D, Hebert M, Smink K, et al. Double blind randomized trial of sucralfate vs. placebo during radiotherapy for head and neck cancers. Head Neck 1999;21:760–766.PubMedCrossRefGoogle Scholar
  56. 56.
    Cengiz M, Ozyar E, Akol F, et al. Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol 1999;28:40–43.PubMedCrossRefGoogle Scholar
  57. 57.
    Franzen L, Henriksson R, Littbrand B, et al. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncol 1995;34:219–223.PubMedCrossRefGoogle Scholar
  58. 58.
    Lievens Y, Haustermans K, Van der Weyngaert D, et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998;47:149–153.PubMedCrossRefGoogle Scholar
  59. 59.
    Makkonen T, Bostrom P, Vilja P, et al. Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 1994;30:177–182.PubMedGoogle Scholar
  60. 60.
    Matejka M, Nell A, Kment G, et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg 1990;28:89–91.PubMedCrossRefGoogle Scholar
  61. 61.
    Porteder H, Rausch E, Kment G, et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo-and radiotherapy. J Craniomaxillofac Surg 1988;16:371–374.PubMedGoogle Scholar
  62. 62.
    Sironi M, Pozzi P, Polentarutti N, et al. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 1996;8:710–716.PubMedCrossRefGoogle Scholar
  63. 63.
    Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer (Phila) 2001;92:875–885.PubMedCrossRefGoogle Scholar
  64. 64.
    Ferretti G, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy-and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol 1990;69:331–338.PubMedCrossRefGoogle Scholar
  65. 65.
    Spijkervet F, van Saene HK, Panders AK, et al. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 1989;67:154–161.PubMedCrossRefGoogle Scholar
  66. 66.
    Foote R, Loprinzi C, Frank A, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994;12:2630–2633.PubMedGoogle Scholar
  67. 67.
    Spijkervet F, van Saene HK, van Saene JJ, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 1991;46:167–173.PubMedCrossRefGoogle Scholar
  68. 68.
    Okuno S, Foote RL, Loprinzi CL, et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiationinduced mucositis. Cancer (Phila) 1997;79:2193–2199.PubMedCrossRefGoogle Scholar
  69. 69.
    Symonds R, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996;74:312–317.PubMedGoogle Scholar
  70. 70.
    Wijers O, Levendag P, Harms E, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001;50:343–352.PubMedCrossRefGoogle Scholar
  71. 71.
    El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiationassociated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002;20:3956–3963.PubMedCrossRefGoogle Scholar
  72. 72.
    Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head and neck malignancy. Int J Radiat Oncol Biol Phys 2004;58:674–681.PubMedCrossRefGoogle Scholar
  73. 73.
    Dodd M, Dibble S, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:39–47.PubMedGoogle Scholar
  74. 74.
    Beumer J, Silverman S Jr, Benak SB Jr. Hard and soft tissue necrosis following radiation therapy for oral cancer. J Prosthet Dent 1972;27:640–644.PubMedCrossRefGoogle Scholar
  75. 75.
    Epstein J, Rea, G, Wong, FL, Spinelli J, Stevenson-Moore P. Osteoradionecrosis: study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg 1987;10:48–54.PubMedCrossRefGoogle Scholar
  76. 76.
    Schweiger J. Oral complications following radiation therapy: A five-year retrospective report. J Prosthet Dent 1987;58:78–82.PubMedCrossRefGoogle Scholar
  77. 77.
    Marx R, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1987;64:379–390.Google Scholar
  78. 78.
    Mansfield M, Sanders DW, Heimbach RD. Hyperbaric oxygen as an adjunct in the treatment of osteoradionecrosis of the mandible. J Oral Surg 1981;39:585–589.PubMedGoogle Scholar
  79. 79.
    Farmer J, Shelton PL, Angelillo JF. Treatment of radiation induced tissue injury by hyperbaric oxygen. Ann Otolaryngol 1978;87:707–715.Google Scholar
  80. 80.
    Barrett V, Martin JW, Jacob RF. Physical therapy techniques in the treatment of the head and neck patient. J Prosthet Dent 1988;59:343–346.PubMedCrossRefGoogle Scholar
  81. 81.
    Rocabardo M, Johnston BE, Blakney MG. Physical therapy and dentistry: an overview. J Craniomand Pract 1983;1:46–49.Google Scholar
  82. 82.
    Morton M, Simpson W. The management of osteoradionecrosis of the jaws. Br J Oral Maxillofac Surg 1986;24:332–341.PubMedCrossRefGoogle Scholar
  83. 83.
    Ritchie J, Brown JR, Guerra LR, Mason G. Dental care for the irradiated dental patient. Quintessence Int 1985;12:837–842.Google Scholar
  84. 84.
    Mealey B, Semba SE, Hallmon WW. The head and neck radiotherapy patient. Part 2. Management of oral complications. Compendium Cont Educ Dent 1994;15:442–458.Google Scholar
  85. 85.
    Fattore L, Strauss R, Bruno J. The management of periodontal disease in patients who have received radiation therapy for head and neck cancer. Spec Care Dentist 1987;120–123.Google Scholar
  86. 86.
    Epstein J, Wong FL, Stevenson-Moore P. Osteoradionecrosis: clinical experience and a proposal for classification. J Oral Maxillofac Surg 1987;45:104–110.PubMedGoogle Scholar
  87. 87.
    Fujita M, Tanimoto K, Wada T. Early radiographic changes in radiation bone injury. Oral Surg Oral Med Oral Pathol 1986;61:641–644.PubMedCrossRefGoogle Scholar
  88. 88.
    McClure D, Barker G, Barker B, Feil P. Oral management of the cancer patient. Part II. Oral complications of radiation therapy. Compendium Cont Educ Dent 1987;8:88–92.Google Scholar
  89. 89.
    Pappas G. Oral roentgenology. Bone changes in osteoradionecrosis: a review. Oral Surg Oral Med Oral Pathol 1969;27:622–630.PubMedCrossRefGoogle Scholar
  90. 90.
    Bundgaard T, Tandrup O, Elbrond O. A functional evaluation of patients treated for oral cancer. A prospective study. Int J Oral Maxillofac Surg 1993;22:28–34.PubMedCrossRefGoogle Scholar
  91. 91.
    Granstrom G, Jacobsson M, Tjellstrom A. Titanium implants in irradiated tissues: benefits from hyperbaric oxygen. Int J Oral Maxillofac Impl 1992;7:15–25.Google Scholar
  92. 92.
    Liu R, Fleming TJ, Toth BB. Salivary flow rates in patients with head and neck cancer 0.5 to 25 years after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1990;70:724–729.Google Scholar
  93. 93.
    Mandel I. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989;119:298–303.PubMedGoogle Scholar
  94. 94.
    Stephens L, Schultheiss TE, Price RE, Ang KK, Peters LJ. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer (Phila) 1991;67:1539–1543.PubMedCrossRefGoogle Scholar
  95. 95.
    Schubert M, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. J Dent Res 1987;66(S):680–688.PubMedGoogle Scholar
  96. 96.
    Keene H, Fleming TJ. Prevalence of caries-associated microflora after radiotherapy in patients with cancer of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1987;64:421–426.Google Scholar
  97. 97.
    Toljanic J, Saunders VW Jr. Radiation therapy and management of the irradiated patient. J Prosthet Dent 1984;52:852–858.PubMedCrossRefGoogle Scholar
  98. 98.
    Keene H, Fleming TJ, Toth BB. Cariogenic microflora in patients with Hodgkin’s disease before and after mantle field radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1994;78:577–581.Google Scholar
  99. 99.
    Engelmeier R. A dental protocol for patients receiving radiation therapy for cancer of the head and neck. Spec Care Dentist 1987;7:54–58.PubMedGoogle Scholar
  100. 100.
    Warde P, Kroll B, O’Sullivan B, et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 2000;8:203–208.PubMedCrossRefGoogle Scholar
  101. 101.
    Johnson J, Feretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390–395.PubMedCrossRefGoogle Scholar
  102. 102.
    LeVeque F, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124–1131.PubMedGoogle Scholar
  103. 103.
    Fife R, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 2002;162:1293–1300.PubMedCrossRefGoogle Scholar
  104. 104.
    Warde P, O’Sullivan B, Aslanidis J, et al. A Phase III placebocontrolled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9–13.PubMedCrossRefGoogle Scholar
  105. 105.
    Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer: RTOG 97-09. Int J Radiat Oncol Biol Phys 2003;56:832–836.PubMedCrossRefGoogle Scholar
  106. 106.
    Rode M, Smid L, Budihna M, Soba E, Rode M, Gaspersic D. The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. Int J Radiat Oncol Biol Phys 1999;45:373–378.PubMedCrossRefGoogle Scholar
  107. 107.
    Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48:1035–1039.PubMedCrossRefGoogle Scholar
  108. 108.
    Cassatt D, Fazenbaker C, Kifle G, et al. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 2003;57:794–802.PubMedCrossRefGoogle Scholar
  109. 109.
    Anne P. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 2002;29:80–83.PubMedGoogle Scholar
  110. 110.
    Koukourakis M, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2002;18:2226–2233.Google Scholar
  111. 111.
    Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002;29:57–60.PubMedCrossRefGoogle Scholar
  112. 112.
    Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 2003;66:283–289.PubMedCrossRefGoogle Scholar
  113. 113.
    Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45:577–587.PubMedCrossRefGoogle Scholar
  114. 114.
    Chao KSC, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907–916.PubMedCrossRefGoogle Scholar
  115. 115.
    Eisbruch A, Kim H, Terrell J, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695–704.PubMedCrossRefGoogle Scholar
  116. 116.
    Chao K, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61:275–280.PubMedCrossRefGoogle Scholar
  117. 117.
    Lee N, Xia P, Quivey J, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12–22.PubMedCrossRefGoogle Scholar
  118. 118.
    Fleming I, Brady LW, Mieszkalski GB, Cooper MR. Basis for major current therapies for cancer. In: Murphy GPLW, Lenhard RE (eds). American Cancer Society Textbook of Clinical Oncology, 2nd ed. Atlanta: The American Cancer Society, 1995:96–134.Google Scholar
  119. 119.
    Heimdahl A, Mattsson T, Dahllöf G, Lonnquist B, Ringdén O. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989;68:711–716.PubMedCrossRefGoogle Scholar
  120. 120.
    Cutler L. Evaluation and management of the dental patient with cancer. I. Complications associated with chemotherapy or bone marrow transplantation. J Conn State Dent Assoc 1987;61:236–238.PubMedGoogle Scholar
  121. 121.
    Toth B, Martin JW, Fleming TJ. Oral complications associated with cancer therapy: an M.D. Anderson Cancer Center experience. J Clin Periodontol 1990;17:508–515.PubMedCrossRefGoogle Scholar
  122. 122.
    Overholser C, Peterson DE, Williams LT, Schimpff SC. Periodontal infection of patients with acute nonlymphocyte leukemia: prevalence of acute exacerbations. Arch Intern Med 1982;142:551–554.PubMedCrossRefGoogle Scholar
  123. 123.
    Peterson D, Minah GE, Overholser CD, et al. Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol 1987;5:1461–1468.PubMedGoogle Scholar
  124. 124.
    Bodey G. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–340.PubMedGoogle Scholar
  125. 125.
    Epstein J, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1992;73:682–689.PubMedCrossRefGoogle Scholar
  126. 126.
    Ferretti G, Hansen IA, Whittenburg K, Brown AT, Lillich TT, Ash RC. Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1987;63:683–687.Google Scholar
  127. 127.
    Ferretti G, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987;114:461–467.PubMedGoogle Scholar
  128. 128.
    Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatr Dent 1989;11:37–42.PubMedGoogle Scholar
  129. 129.
    Rutkauskas J, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report. Oral Surg Oral Med Oral Pathol 1993;76:441–448.PubMedCrossRefGoogle Scholar
  130. 130.
    Thurmond J, Brown AT, Sims RE, et al. Oral Candida albicans in bone marrow transplant patients given chlorhexidine rinses: occurrence and susceptibilities to the agent. Oral Surg Oral Med Oral Pathol 1991;72:291–295.PubMedCrossRefGoogle Scholar
  131. 131.
    Lenhard R, Lawrence W, McKenna RJ. General approach to the patient. In: Murphy GPLW, Lenhard RE (eds). American Cancer Society Textbook of Clinical Oncology, 2nd ed. Atlanta: The American Cancer Society, 1995:64–74.Google Scholar
  132. 132.
    Cheatham B, Henry RJ. A dental complication involving Pseudomonas during chemotherapy for acute lymphoblastic leukemia. J Clin Pediatr Dent 1994;18:215–217.PubMedGoogle Scholar
  133. 133.
    Kaminski S, Gillette WB, O’Leary TJ. Sodium absorption associated with oral hygiene procedures. J Am Dent Assoc 1987;114:644–646.Google Scholar
  134. 134.
    Maeda H, Kameyama Y, Nakane S, Takehana S, Sato E. Epithelial dysplasia produced by carcinogen pretreatment and subsequent wounding. Oral Surg Oral Med Oral Pathol 1989;68:50–56.PubMedCrossRefGoogle Scholar
  135. 135.
    O’Sullivan E, Duggal MS, Bailey CC, Curzon MEJ, Hart P. Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia. Oral Surg Oral Med Oral Pathol 1993;76:161–168.PubMedCrossRefGoogle Scholar
  136. 136.
    Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994;30B:93–97.PubMedCrossRefGoogle Scholar
  137. 137.
    Lefkoff M, Beck FM, Horton JE. The effectiveness of a disposable tooth cleansing device on plaque. J Periodontol 1995;66:218–221.PubMedGoogle Scholar
  138. 138.
    Brown A, Shupe JA, Sims RE, et al. In vitro effect of chlorhexidine and amikacin on oral gram-negative bacilli from bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1990;70:715–719.PubMedCrossRefGoogle Scholar
  139. 139.
    Semba S, Mealey BL, Hallmon WW. Dentistry and the cancer patient. Part 2. Oral health management of the chemotherapy patient. Compendium Cont Educ Dent 1994;15:1378–1388.Google Scholar
  140. 140.
    Drugs of choice for cancer chemotherapy. Med Lett 1995;37:25–32.Google Scholar
  141. 141.
    Pizzo P. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323–1332.PubMedCrossRefGoogle Scholar
  142. 142.
    Sager R, Theis RM. Dental implants placed in a patient with multiple myeloma: report of a case. J Am Dent Assoc 1990;121:699–701.PubMedGoogle Scholar
  143. 143.
    Vassos D. Dental implant treatment in a severely compromised (irradiated) patient. J Oral Implantol 1992;18:142–147.PubMedGoogle Scholar
  144. 144.
    Karr R, Kramer DC. You can treat the chemotherapy patient. Texas Dent J 1992;109:15–20.PubMedGoogle Scholar
  145. 145.
    Toth B, Frame RT. Dental oncology: the management of disease and treatment-related oral/dental complications associated with chemotherapy. Curr Probl Cancer 1983;7:7–35.PubMedCrossRefGoogle Scholar
  146. 146.
    Sonis S. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39–43.PubMedCrossRefGoogle Scholar
  147. 147.
    Schubert M, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation: development of an oral mucositis index. Cancer (Phila) 1991;69:2469–2477.CrossRefGoogle Scholar
  148. 148.
    Sonis S, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer (Phila) 1999;85:2103–2113.PubMedCrossRefGoogle Scholar
  149. 149.
    Montgomery M, Redding SW, LeMaistre CF. The incidence of oral herpes simplex virus infection in patients undergoing cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1986;61:238–242.PubMedCrossRefGoogle Scholar
  150. 150.
    MacPhail L, Hilton JF, Heinic GS, Greenspan D. Direct immunofluorescence vs. culture for detecting HSV in oral ulcers: a comparison. J Am Dent Assoc 1995;126:74–78.PubMedGoogle Scholar
  151. 151.
    Tang I, Shepp DH. Herpes simplex virus infection in cancer patients: prevention and treatment. Oncology 1992;6:101–109.PubMedGoogle Scholar
  152. 152.
    Flaitz C, Hammond HL. The immunoperoxidase method for the rapid diagnosis of intraoral herpes simplex virus infection in patients receiving bone marrow transplants. Spec Care Dentist 1988;8:82–85.PubMedCrossRefGoogle Scholar
  153. 153.
    Greenberg M. Oral herpes simplex infections in patients with leukemia. J Am Dent Assoc 1987;114:483–486.PubMedGoogle Scholar
  154. 154.
    Wade J, Schmiff SC, Newman KA. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982;97:503–508.PubMedGoogle Scholar
  155. 155.
    Meurman J, Pyrhönen S, Teerenhovi L, Lindqvist C. Oral sources of septicaemia in patients with malignancies. Oral Oncol 1997;33:389–397.PubMedCrossRefGoogle Scholar
  156. 156.
    Eting L, Bodey GP, Keefe BH. Septicema and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201–1207.Google Scholar
  157. 157.
    Bez C, Demarosi F, Sardella A, et al. GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:311–315.PubMedCrossRefGoogle Scholar
  158. 158.
    Rosenberg S. Oral care of chemotherapy patients. Dent Clin N Am 1990;34:239–250.PubMedGoogle Scholar
  159. 159.
    Allard W, el-Akkad S, Chatmas JC. Obtaining pre-radiation therapy dental clearance. J Am Dent Assoc 1993;124:88–91.PubMedGoogle Scholar
  160. 160.
    Barrett A, Buckley DJ. Oral complications of high-dose melphalan in multiple myeloma. Oral Surg Oral Med Oral Pathol 1987;64:264–267.PubMedCrossRefGoogle Scholar
  161. 161.
    Carl W. Managing the oral manifestations of cancer therapy. Part II. Chemotherapy. Compendium Cont Educ Dent 1988;9:376–386.Google Scholar
  162. 162.
    McCarthy G, Skillings JR. Orofacial complications of chemotherapy for breast cancer. Oral Surg Oral Med Oral Pathol 1992;74:172–178.PubMedCrossRefGoogle Scholar
  163. 163.
    Mealey B, Semba SE, Hallmon WW. Dentistry and the cancer patient. Part I. Oral manifestations and complications of chemotherapy. Compendium Cont Educ Dent 1994;xv:1252–1256.Google Scholar
  164. 164.
    Ramos L. Oral aspects of chemotherapy: patient information. Texas Dent J 1994;111(6):42–45.PubMedGoogle Scholar
  165. 165.
    Poland J. Prevention and treatment of oral complications in the cancer patient. Oncology 191;5:45–62.Google Scholar
  166. 166.
    Epstein J, Sherlock CH, Page JL, Spinelli J, Phillips G. Clinical study of herpes simplex virus infection in leukemia. Oral Surg Oral Med Oral Pathol 1990;70:38–43.PubMedCrossRefGoogle Scholar
  167. 167.
    Toth B, Martin JW, Chambers MS, Lippman SM. Oral cancer, leukoplakia, and chemoprevention. Oral Disease Update 1997;3:8–9.Google Scholar
  168. 168.
    Cooper B. New concepts in management of acute leukemia. BUMC Proc 1990;3:31–33.Google Scholar
  169. 169.
    Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllöf G, Ringdén O. Alterations in test acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 1992;21:33–37.PubMedCrossRefGoogle Scholar
  170. 170.
    Barasch A, Safford MM. Management of oral pain in patients with malignant diseases. Compendium Cont Educ Dent 1993;14:1376–1383.Google Scholar
  171. 171.
    Collins R, Miller GW, Fay JW. Autologous bone marrow transplantation: a review. BUMC Proc 1991;4:3–12.Google Scholar
  172. 172.
    Dahllöf G, Heimdahl A, Modéer T, Twetman S, Bolme P, Ringdén O. Oral mucous membrane lesions in children treated with bone marrow transplantation. Scand J Dent Res 1989;97:268–277.PubMedGoogle Scholar
  173. 173.
    Maxymiw W, Wood RE. The role of dentistry in patients undergoing bone marrow transplantation. Br Dent J 1989;167:229–234.PubMedCrossRefGoogle Scholar
  174. 174.
    Birek C, Patterson B, Maximi WC, Minden MD. EBV and HSV infections in a patient who had undergone bone marrow transplantation: oral manifestations and diagnosis by in situ nucleic acid hybridization. Oral Surg Oral Med Oral Pathol 1989;68:612–617.PubMedCrossRefGoogle Scholar
  175. 175.
    LeVeque F, Ratanatharathorn V, Danielsson KH, Orville B, Coleman DN, Turner S. Oral cytomegalovirus infection in an unrelated bone marrow transplantation with possible mediation by graft-versus-host disease and the use of cyclosporin? Oral Surg Oral Med Oral Pathol 1994;77:248–253.PubMedCrossRefGoogle Scholar
  176. 176.
    Schubert M, Peterson DE, Flournoy N, Meyers J, Truelove EL. Oral and pharyngeal herpes simplex virus infection following bone marrow transplantation: analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990;70:286–293.PubMedCrossRefGoogle Scholar
  177. 177.
    Schuchter L, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:1424–1427.PubMedGoogle Scholar
  178. 178.
    Vose J, Kennedy BC, Bierman PJ, Kessinger A, Armitage JO. Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer (Phila) 1992;69:784–789.PubMedCrossRefGoogle Scholar
  179. 179.
    Schubert M, Epstein JB, Lloyd ME, Cooney E. Oral infections due to cytomegalovirus in immunocompromised patients. J Oral Pathol Med 1993;22:268–273.PubMedCrossRefGoogle Scholar
  180. 180.
    Barrett A, Schifter M. Antibiotic strategy in orofacial/head and neck infections in severe neutropenia. Oral Surg Oral Med Oral Pathol 1994;77:350–355.PubMedCrossRefGoogle Scholar
  181. 181.
    Mattsson T, Heimdahl A, Dahllöf G, Ma DQ, Ringden O. Oral and nutritional status in allogeneic marrow recipients treated with T-cell depletion or cyclosporine combined with methotrexate to prevent graft-versus-host disease. Oral Surg Oral Med Oral Pathol 1992;74:34–40.PubMedCrossRefGoogle Scholar
  182. 182.
    Epstein J, Sherlock CH, Wolber RA. Hairy leukoplakia after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1993;75:690–695.PubMedCrossRefGoogle Scholar
  183. 183.
    Peterson D. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr 1990;9:61–71.PubMedGoogle Scholar
  184. 184.
    Ferrara J, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667–674.PubMedCrossRefGoogle Scholar
  185. 185.
    Curtis JJ, Caughman GB. An apparent unusual relationship between rampant caries and graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1991;78:267–272.Google Scholar
  186. 186.
    Hiroki A, Nakamura S, Shinohara M, Oka M. Significance of oral examination in chronic graft-versus-host disease. J Oral Pathol Med 194;23:209–215.Google Scholar
  187. 187.
    Heimdahl A, Johnson G, Danielsson KH, Lönnquist B, Sundelin P, Ringdén O. Oral condition of patients with leukemia and severe aplastic anemia. Follow-up one year after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1985;60:498–504.PubMedCrossRefGoogle Scholar
  188. 188.
    LeVeque F. An unusual presentation of chronic graft-versus-host disease in an unrelated bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1990;69:581–584.PubMedCrossRefGoogle Scholar
  189. 189.
    Barrett A. Graft-versus-host disease. A clinicopathologic review. Ann Dent 1987;46:7–11.PubMedGoogle Scholar
  190. 190.
    Allen C, Kapoor N. Verruciform xanthoma in a bone marrow transplant recipient. Oral Surg Oral Med Oral Pathol 1993;75:591–594.PubMedCrossRefGoogle Scholar
  191. 191.
    Wingard J, Niehaus CS, Peterson DE, et al. Oral mucositis after bone marrow transplantation. A marker of treatment toxicity and predictor of hepatic veno-occlusive disease. Oral Surg Oral Med Oral Pathol 1991;72:419–424.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Mark S. Chambers
    • 1
    • 2
  • Adam S. Garden
    • 3
  1. 1.Head & Neck SurgeryM. D. Anderson Cancer CenterHoustonUSA
  2. 2.Section of Oncologic Dentistry and ProsthodonticsM. D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations